• Mashup Score: 14

    Numerous studies have pointed to a link between new-onset diabetes and pancreatic cancer. Now, several large NCI-supported studies are testing ways to pick out those people whose diabetes might be a sign of early pancreatic cancer, when treatments may be more effective.

    Tweet Tweets with this article
    • RT @theNCI: Could a Diabetes Diagnosis Help Detect Pancreatic Cancer Early? https://t.co/4PcpeoVftm #NCICancerCurrentsblog #repost https://…

  • Mashup Score: 4

    The antibiotic novobiocin showed promise as a treatment for cancers with BRCA mutations that have become resistant to PARP inhibitors. It will soon be tested in NCI-supported clinical trials. The drug inhibits a protein called Pol theta. Another Pol theta inhibitor, ART558, was effective in mice with resistant tumors.

    Tweet Tweets with this article
    • Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors? https://t.co/C9xYhr0Zgu #NCICancerCurrentsblog #repost https://t.co/di1bTnu2vj

  • Mashup Score: 2

    Cancer can greatly disrupt the lives of adolescents and young adults, who are already going through major life transitions. A new task force will help researchers gather much-needed data on how cancer and its treatment affect this age group, with the aim of improving their quality of life during and beyond treatment.

    Tweet Tweets with this article
    • New Task Force Focuses on Quality of Life for Adolescents and Young Adults with Cancer: https://t.co/A4MhUoXgJs #AYAcancer #repost https://t.co/39FqbSVdts

  • Mashup Score: 7

    FDA’s approval of a new form of asparaginase called Rylaze should alleviate shortages of Erwinia asparaginase, a key part of treatment for children and adults with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma, a rare cancer that resembles ALL.

    Tweet Tweets with this article
    • A new drug approval is expected to help address a critical need for some children with acute lymphoblastic #leukemia: https://t.co/GG2addFTzw #repost https://t.co/9Ib4T9bWhy

  • Mashup Score: 4

    The antibiotic novobiocin showed promise as a treatment for cancers with BRCA mutations that have become resistant to PARP inhibitors. It will soon be tested in NCI-supported clinical trials. The drug inhibits a protein called Pol theta. Another Pol theta inhibitor, ART558, was effective in mice with resistant tumors.

    Tweet Tweets with this article
    • Can an #antibiotic treat cancers that become resistant to PARP inhibitors? https://t.co/C9xYhr0Zgu #repost https://t.co/PzdFYqd1S9

  • Mashup Score: 9

    Researchers have identified a specific pattern of damaged DNA in people with colorectal cancer who ate a lot of red meat. The link between these mutational signatures and the consumption of red and processed meats further implicates diet in the development of colorectal cancer, experts say.

    Tweet Tweets with this article
    • #ICYMI: Pattern of DNA damage links #ColorectalCancer and diet high in red meat https://t.co/5vFEKf6yxm #repost https://t.co/pAj81zva6U

  • Mashup Score: 3

    This page highlights what’s new and recent research in the treatment of melanoma and other skin cancers, including targeted therapies, immune checkpoint inhibitors, and adoptive cell transfer. Selected NCI-supported programs to address these cancers are also described.

    Tweet Tweets with this article
    • What's happening in research on #melanoma and other skin cancers? Here's a summary of some of the latest research advances in treatments for these diseases. https://t.co/yRPYNZqdMc #Repost https://t.co/hQ03YAWgoV

  • Mashup Score: 10

    Dr. Steven Pergam of the Fred Hutchinson Cancer Research Center discusses the importance of COVID-19 vaccination for people being treated for cancer and cancer survivors. This post was updated on April 9, 2021, with additional questions and answers.

    Tweet Tweets with this article
    • In this Q&A, Dr. Steven Pergam discusses questions people with cancer and cancer survivors may have about #COVID19 vaccines. @FredHutch @PergamIC #repost https://t.co/qXOsrm5Gw7 https://t.co/eKvHuKURmW

  • Mashup Score: 5

    Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.

    Tweet Tweets with this article
    • The drug sacituzumab govitecan (Trodelvy) now has regular @US_FDA approval for people with locally advanced or metastatic triple-negative breast cancer: https://t.co/9gYUYK8Wp4 #NCICancerCurrentsblog #repost https://t.co/ST2UWg8aT0